Investors Buy Becton Dickinson and (BDX) on Weakness on Insider Selling
Traders purchased shares of Becton Dickinson and Co (NYSE:BDX) on weakness during trading on Friday after an insider sold shares in the company. $70.80 million flowed into the stock on the tick-up and $52.40 million flowed out of the stock on the tick-down, for a money net flow of $18.40 million into the stock. Of all stocks tracked, Becton Dickinson and had the 30th highest net in-flow for the day. Becton Dickinson and traded down ($0.47) for the day and closed at $217.65Specifically, Director Timothy M. Ring sold 176 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $218.27, for a total value of $38,415.52. Following the sale, the director now directly owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP James W. Borzi sold 4,048 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $224.98, for a total value of $910,719.04. Following the completion of the sale, the executive vice president now directly owns 5,334 shares in the company, valued at $1,200,043.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 279,231 shares of company stock worth $60,895,317. 1.00% of the stock is owned by insiders.
Several brokerages recently weighed in on BDX. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target on the stock in a research note on Friday, January 19th. Bank of America reissued a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research note on Friday, January 19th. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 target price (up from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Morgan Stanley increased their target price on Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research note on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $237.27.
The stock has a market capitalization of $57,950.00, a price-to-earnings ratio of 87.41, a PEG ratio of 1.59 and a beta of 1.18. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is currently 120.48%.
Large investors have recently made changes to their positions in the company. Legacy Advisors LLC lifted its holdings in shares of Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after purchasing an additional 490 shares in the last quarter. Amica Retiree Medical Trust lifted its holdings in shares of Becton Dickinson and by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after purchasing an additional 390 shares in the last quarter. Almanack Investment Partners LLC. bought a new position in shares of Becton Dickinson and during the fourth quarter valued at $109,000. FTB Advisors Inc. lifted its holdings in shares of Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 290 shares in the last quarter. Finally, Advisors Preferred LLC bought a new position in shares of Becton Dickinson and during the fourth quarter valued at $126,000. 77.50% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.dailypolitical.com/2018/03/03/investors-buy-becton-dickinson-and-bdx-on-weakness-on-insider-selling.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.